2006 Fixed dose association of phytate and zinc for the treatment of crystallization of hydroxyapatite

Researchers at the University have patented a fixed-dose association of phytate and zinc in synergistic proportions to be used in the treatment of crystallization of hydroxyapatite

The pathological crystallization is a consequence of the imbalance between three groups of factors: supersaturation, crystallization promoters and crystallization repressors. Calcifications are frequently found in the cardiovascular system, altering the flexibility of blood vessels and promoting thrombosis and arterial rupture, which can lead to heart failure and death.


Crystallization inhibitors are substances that hinder or prevent the development of crystals. Myo-inositol hexaphosphate, which is known as the most powerful inhibitor against the development of calcium salts.

That is why researchers from the University have patented a fixed-dose combination of phytate and zinc with isneglectic effects in inhibiting the crystallization of hydroxyapatite because this association can be used for the manufacture of a drug for the treatment, prophylaxis and / or to the prevention of the crystallization of human hydroxyapatite.

Main advantages

  • Association of fixed dose of phytate and zinc that allows the inhibition of the crystallization of hydroxyapatite with good results
  • It can be administered in the form of mouthwash, vitamin supplement or other forms

Innovative aspects

  • Increase of the inhibiting effect of the crystallization of the phytate
  • Increase in the level of inhibition of crystallization by 50%

Actual state

Currently, this invention is transferred and protected by a patent in several countries: Australia, Brazil, Canada, China, Spain, Mexico, Norway, Russia and the USA.

Amb la col·laboració de:

Logotipus del Ministeri de Ciència, Innovació i Universitats